13F Holdings
中文EN

PRAX Praxis Precision Medicines, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1689548 · Fiscal year ends 12/31

Financial factors as of 2025-09-30 (2025Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY365.0%
TTM net income YoY-80.8%
TTM EPS YoY-41.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-3,927.5%
Net margin-3,658.5%
FCF margin-3,067.4%
EBITDA margin-3,925.4%

Returns

ROE-75.2%
ROA-67.2%
ROIC (approx.)-113.5%
Asset turnover0.02x

Leverage & solvency

Liabilities / assets13.3%
Debt / equity0.00x
Current ratio5.18x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.84x
Accruals ratio-10.9%
Payout ratio—
Capex / revenue0.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$0$8.55M$2.45M$0—
R&D expense$267.12M$152.41M$86.77M$155.04M$120.26M
SG&A expense$59.08M$56.30M$42.05M$59.95M$47.08M
Operating income-$326.20M-$200.16M-$126.37M-$214.99M-$167.33M
Pretax income-$302.80M-$182.74M-$123.01M—-$167.06M
Income tax$471,000———$0
Net income-$303.27M-$182.82M-$123.28M-$214.03M-$167.06M
EBITDA-$326.06M-$199.81M-$125.94M-$214.57M-$167.15M
EPS (basic)-13.48-10.21-18.69-69.65-3.94
EPS (diluted)-13.48-10.21-18.69-69.65-3.94
Weighted avg. shares (diluted)22.50M17.91M6.59M3.07M42.45M
Balance sheet
Cash & equivalents$357.33M$215.79M$81.30M$62.03M$139.72M
Short-term investments$242.00M$177.19M$0$38.87M$105.68M
Current assets$610.91M$404.37M$84.88M$110.84M$287.41M
PP&E, net$147,000$230,000$588,000$971,000$1.21M
Intangibles$0————
Total assets$937.91M$483.11M$87.95M$115.13M$292.75M
Current liabilities$59.77M$37.55M$15.75M$34.34M$38.43M
Total liabilities$59.77M$37.66M$18.28M$39.02M$41.94M
Shareholders' equity$878.14M$445.45M$69.67M$76.11M$250.81M
Shares outstanding25.20M19.42M8.79M3.29M45.30M
Cash flow statement
Operating cash flow-$249.07M-$131.76M-$111.14M-$185.04M-$124.55M
Capital expenditure$56,000$0$50,000$444,000$1.05M
Free cash flow-$249.12M-$131.76M-$111.19M-$185.49M-$125.60M
Investing cash flow-$311.15M-$248.49M$38.95M$96.89M-$140.52M
Financing cash flow$702.17M$514.32M$91.87M$10.46M$107.59M
Depreciation & amortization$140,000$358,000$432,000$419,000$182,000
Stock-based compensation$33.94M$41.36M$24.86M$28.59M$22.69M

Free plan shows the latest 5 periods; Pro shows all 7 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.